Related Experiment Videos
No evidence of somatic FGFR3 mutation in various types of carcinoma
M Karoui1, H Hofmann-Radvanyi, U Zimmermann
1Fédération des Spécialités Digestives, Hôpital Ambroise Paré, Université Paris V, 92104 Boulogne Cedex, France.
Abstract:
Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.
Insights
Fibroblast growth factor receptor 3 (FGFR3) gene mutations are linked to skeletal disorders and some cancers. This study found no FGFR3 mutations in various common tumors, suggesting they are specific to bladder cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Germline mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are known to cause skeletal dysplasias and craniosynostosis syndromes.
- Activating FGFR3 mutations, similar to those in skeletal disorders, have been identified in various cancers, notably bladder carcinoma.
- The prevalence and specificity of FGFR3 mutations across different cancer types require further investigation.
Purpose of the Study:
- To investigate the prevalence of FGFR3 gene mutations in a diverse range of primary human tumors.
- To determine if FGFR3 mutations, previously associated with skeletal conditions and bladder cancer, occur in other common cancer types.
Main Methods:
- Analysis of 116 primary tumors from the upper aerodigestive tract, esophagus, stomach, lung, and skin.
- Utilized Single-Strand Conformation Polymorphism (SSCP) and DNA sequencing to detect mutations.
- Focused analysis on regions known to harbor previously described FGFR3 point mutations in skeletal dysplasias and cancers.
Main Results:
- No FGFR3 mutations were detected in any of the analyzed tumor types (upper aerodigestive tract, esophagus, stomach, lung, skin).
- This finding contrasts with the known high frequency of FGFR3 mutations in bladder carcinoma.
- The results indicate that FGFR3 mutations are not a common feature in the investigated tumor spectrum.
Conclusions:
- The study suggests that FGFR3 mutations are restricted to a limited set of tumor types.
- Current evidence strongly points towards FGFR3 mutations being highly specific to bladder carcinomas.
- Further research may elucidate the precise oncogenic role and specificity of FGFR3 mutations in human cancers.